Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All Tissue/Cell Product Firms Must Register With CBER Under Proposed Rule

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers of human cellular and tissue-based products will be required to register and list their products with the Center for Biologics Evaluation and Research regardless of whether their products fall under the agency's new tissue regulation or continue to be regulated as devices or biologics, FDA says in a May 14 proposed rule.

You may also be interested in...

Human bone allografts

Public meeting scheduled for Aug. 2 at the NIH campus in Bethesda, Maryland, is being organized by FDA's devices and biologics centers to provide a public forum for gathering scientific data, information and views from interested persons about human bone allografts in relation to FDA's proposed tissue rules (1"The Gray Sheet" May 25, 1998, p. 13). Entitled "Human Bone Allograft: Manipulation and Homologous Use in Spine and Other Orthopedic Reconstruction and Repair," the meeting is intended to "provide stakeholders with the opportunity to present additional information to the agency," FDA says. The agency "is requesting specific information concerning the characteristics of various bone products as they relate to the agency's proposed definitions for minimal manipulation and homologous use"

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts